Joindre l'IPC

04 91 22 33 33

 Prendre rendez-vous

04 91 22 30 30

ETOH - early phase senter

To accelerate the evaluation of innovative therapeutic approaches but also to ensure the level of care and quality of the process imposed by this type of trial, the IPC has created ETOH (Evaluation of Therapeutic Onco-Hematology), a unit dedicated exclusively to early clinical trials.

Approved and labeled by the ARS and granted by INCa in 2010, ETOH is the platform of PACA region for evaluating new drugs (in solid tumors and hematology).

Installed on 250 sqm on the 5th floor of the main building (IPC1), the ETOH unit is run by a highly specialized team of 16 people. It has 9 single rooms (5 beds are available on an outpatient basis), a treatment room, monitoring tools and a specific area allowing immediate treatment of blood and urine samples.

In addition to medical expertise of the Institute (surgery, radiotherapy, transplant ...), the team relies on the Therapeutic Intensive Care Unit (specializing in the care of patients with hematologic malignancies) and common technology platforms of the IPC and CRCM: scientific imaging, integrated biology, immunomonitoring, biobank ... administratively, the tests are monitored by the Department of Clinical Research and Innovation (DRCI).

To date ETOH has already led studies of 44 patients (19 in 2010 and 22 in 2011) among which the first administration in man of two drug candidates.

 

Management & contact: Pr Norbert Vey and Dr Anthony Gonçalves

Date of creation: 2010

Location: IPC

Staff (IPC and others):  4 MDs (including the 2 directors), 9 collaborating physicians (oncologists, hematologists and 1 radiologist), 1 research nurse, 1 clinical research assistant, 1 technician